Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant what is the number needed to treat, number needed to harm and likelihood to be helped or harmed
International Journal of Clinical Practice,  Evidence Based Medicine  Clinical Article

Citrome L – Vilazodone represents another option for the treatment of major depressive disorder (MDD). Vilazodone appears to have a favourable weight–gain profile based on short–term studies. Sexual side–effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long–term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.

Methods
  • The pivotal registration trials were accessed by querying , and for the search term `vilazodone'.
  • Product labeling provided additional information.
  • All available clinical reports of studies were identified.
  • Descriptions of the principal results and calculation of number needed to treat (NNT) and number needed to harm (NNH) for relevant dichotomous outcomes were extracted from the available study reports and other sources of information.

Results
  • Vilazodone is a specific serotonin reuptake inhibitor and serotonin 5HT1A receptor partial agonist.
  • In needs to be administered with food to ensure adequate bioavailability.
  • Approval for the treatment of MDD was based on a clinical development programme that included two 8–week placebo–controlled randomised clinical trials in outpatients with MDD where vilazodone was titrated to a target dose of 40mg/d over the first 2weeks.
  • Both trials evidenced efficacy for vilazodone as measured by the Montgomery Asberg Depression Rating Scale.
  • NNT for response vs. placebo was 8 (95% CI 6–16) and for remission was 14 (95% CI 8–55). NNH vs. placebo for discontinuation because of an adverse event (AE) was 27 (95% CI 15–104).
  • The most commonly encountered AEs (incidence ≥5% and at least twice the rate of placebo) were diarrhoea, nausea, vomiting and insomnia, with NNH values vs. placebo of 6 (95% CI 5–8), 6 (95% CI 5–8), 30 (95% CI 18–82) and 26 (95% CI 16–78), respectively.
  • NNH vs. placebo for any sexual AE was 12 (95% CI 9–18), but systematically collected data using rating scales of sexual function did not reveal treatment associated effects.
  • Vilazodone was not associated with clinically relevant weight change in the short–term trials.
  • In an open–label 1–year study of vilazodone, mean weight increased by 1.7kg among the observed cases.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 Precautionary labelling of foods for allergen content: Are we ready for a global framework? Full Text World Allergy Organization Journal, May 8, 2014    Free full text    Review Article

2 A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: Sorafenib for second line renal cell cancer Full Text Cost Effectiveness and Resource Allocation, May 5, 2014    Free full text

3 Vancomycin, metronidazole, or tolevamer for clostridium difficile infection: Results from two multinational, randomized, controlled trials Clinical Infectious Diseases, June 6, 2014    Clinical Article

4 Maternal high-dose folic acid during pregnancy and asthma medication in the offspring Pharmacoepidemiology and Drug Safety, June 23, 2014    Clinical Article

5 Reprint of “Heated vegetable oils and cardiovascular disease risk factors” Vascular Pharmacology, June 4, 2014    Review Article

6 Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents Expert Opinion on Pharmacotherapy, March 17, 2014    Review Article

7 Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers European Journal of Clinical Pharmacology, June 12, 2014    Clinical Article

8 Cost-effectiveness of cranberries vs antibiotics to prevent urinary tract infections in premenopausal women: a randomized clinical trial PLOS ONE, April 15, 2014    Review Article

9 Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation PharmacoEconomics, April 9, 2014    Clinical Article

10 The effectiveness of metoprolol versus atenolol on prevention of all-cause and cardiovascular mortality in a large Chinese population: A cohort study International Journal of Cardiology, June 27, 2014    Clinical Article

11 Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention JACC Cardiovascular Interventions, June 20, 2014    Clinical Article

12 New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness Full Text Drug Design, Development and Therapy, June 18, 2014    Free full text    Review Article

13 Efficacy of nebulised budesonide versus oral prednisolone in acute severe asthma The Indian Journal of Pediatrics, June 11, 2014    Clinical Article

14 HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial Journal of Acquired Immune Deficiency Syndromes, June 19, 2014    Clinical Article

15 Beyond statins: new lipid lowering strategies to reduce cardiovascular risk Current Atherosclerosis Reports, May 21, 2014    Review Article    Clinical Article

16 Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: A double-blind study The Journal of Allergy and Clinical Immunology, June 13, 2014    Clinical Article

17 The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity Platelets, June 10, 2014    Clinical Article

18 Warfarin dosing and body mass index Annals of Pharmacotherapy, April 21, 2014    Clinical Article

19 Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus Journal of Autoimmunity , June 24, 2014    Review Article

20 Single-dose intra-articular bupivacaine versus morphine after arthroscopic knee surgery: A meta-analysis of randomized-controlled studies The Clinical Journal of Pain, June 10, 2014    Clinical Article

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close